-

03:16:58 AM

BICX Stock News

BICX - BioCorRx Inc

01/27/23 8:30 AM

OTC : BICX

conferenceslow float

BioCorRx to Present at Sequire Biotechnology Conference on February 2nd

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes

RHEA-AI

neutral

01/24/23 9:00 AM

OTC : BICX

managementlow float

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board of

RHEA-AI

very positive

01/19/23 8:30 AM

OTC : BICX

clinical triallow float

BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update from the Phase I clinical trial of BICX104, an implantable

RHEA-AI

neutral

12/07/22 9:00 AM

OTC : BICX

partnershiplow float

BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it has partnered with Government Plus LLC, a leading provider

RHEA-AI

positive

11/22/22 9:00 AM

OTC : BICX

managementlow float

BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of a

RHEA-AI

very positive

11/15/22 9:00 AM

OTC : BICX

low float

BioCorRx Provides Business Update for the Third Quarter of 2022

BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the third quarter ended September 30, 2022 and

RHEA-AI

neutral

10/13/22 8:30 AM

OTC : BICX

clinical triallow float

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the last subject has been enrolled in the Phase I clinical trial

RHEA-AI

neutral

09/06/22 8:30 AM

OTC : BICX

conferenceslow float

BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be

RHEA-AI

neutral

08/16/22 8:30 AM

OTC : BICX

low float

BioCorRx Provides Business Update for the Second Quarter of 2022

via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and

RHEA-AI

neutral

07/13/22 8:30 AM

OTC : BICX

conferenceslow float

BioCorRx to Participate in the Benzinga All Access Event on July 15th

via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO

RHEA-AI

neutral